Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison
Journal of Drugs in Dermatology · 2025
DOI: 10.36849/jdd.8566 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Drugs in Dermatology, 2025. Verfasst von Vardhaman Patel und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Psoriasis, Adalimumab, Scalp Dermatoses. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Patel, V., Hetzel, A., Park, S. H., Hogan, M., Wu, Y., Fillbrunn, M., Patterson-Lomba, O., Swallow, E., & Bagel, J. (2025). Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8566
Vancouver
Patel V, Hetzel A, Park SH, Hogan M, Wu Y, Fillbrunn M, et al. Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison. Journal of Drugs in Dermatology. 2025. doi:10.36849/jdd.8566
BibTeX
@article{Patel2025,
author = {Patel, Vardhaman and Hetzel, Alexa and Park, Sang Hee and Hogan, Malcolm and Wu, Ying and Fillbrunn, Mirko and Patterson-Lomba, Oscar and Swallow, Elyse and Bagel, Jerry},
title = {Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison},
journal = {Journal of Drugs in Dermatology},
year = {2025},
doi = {10.36849/jdd.8566}
}
EUVIMED